NO20073764L - Sammensetninger for behandling av HCV - Google Patents

Sammensetninger for behandling av HCV

Info

Publication number: NO20073764L
Authority: NO; Norway
Prior art keywords: hcv; compositions; treatment; agent; compound
Prior art date: 2004-12-23

Application number

NO20073764A

Other languages

English (en)

Norwegian (no)

Inventor

Kai Lin

Beat Weidmann

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-23

Filing date

2007-07-19

Publication date

2007-09-18

2007-07-19 Application filed by Novartis Ag filed Critical Novartis Ag

2007-09-18 Publication of NO20073764L publication Critical patent/NO20073764L/no

Links

239000000203 mixture Substances 0.000 title 1
102000001493 Cyclophilins Human genes 0.000 abstract 1
108010068682 Cyclophilins Proteins 0.000 abstract 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 1
229930105110 Cyclosporin A Natural products 0.000 abstract 1
108010036949 Cyclosporine Proteins 0.000 abstract 1
229960001265 ciclosporin Drugs 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
229930182912 cyclosporin Natural products 0.000 abstract 1
230000001506 immunosuppresive effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gastroenterology & Hepatology (AREA)
Chemical Kinetics & Catalysis (AREA)
Natural Medicines & Medicinal Plants (AREA)
Virology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Microbiology (AREA)
Botany (AREA)
Medical Informatics (AREA)
Biotechnology (AREA)
Mycology (AREA)
Alternative & Traditional Medicine (AREA)
Zoology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)

NO20073764A 2004-12-23 2007-07-19 Sammensetninger for behandling av HCV NO20073764L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US63867504P	2004-12-23	2004-12-23
PCT/US2005/046059 WO2006071619A1 (en)	2004-12-23	2005-12-20	Compositions for hcv treatment

Publications (1)

Publication Number	Publication Date
NO20073764L true NO20073764L (no)	2007-09-18

Family

ID=36155247

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20073764A NO20073764L (no)	2004-12-23	2007-07-19	Sammensetninger for behandling av HCV

Country Status (16)

Country	Link
US (1)	US7897565B2 (pt)
EP (1)	EP1830871A1 (pt)
JP (1)	JP2008525459A (pt)
KR (1)	KR20070087624A (pt)
CN (1)	CN101076350A (pt)
AU (1)	AU2005322242B2 (pt)
BR (1)	BRPI0519345A2 (pt)
CA (1)	CA2587793A1 (pt)
IL (1)	IL183659A0 (pt)
MA (1)	MA29098B1 (pt)
MX (1)	MX2007007779A (pt)
NO (1)	NO20073764L (pt)
NZ (1)	NZ555143A (pt)
RU (1)	RU2007128099A (pt)
WO (1)	WO2006071619A1 (pt)
ZA (1)	ZA200703908B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0320638D0 (en)	2003-09-03	2003-10-01	Novartis Ag	Organic compounds
KR20070036175A (ko)	2004-07-14	2007-04-02	노파르티스 아게	Ｃ형 간염(ｈｃｖ)의 치료를 위한 시클로스포린과ｐｅｇ화된 인터페론의 조합 제제의 용도
CN101076350A (zh)	2004-12-23	2007-11-21	诺瓦提斯公司	用于hcv治疗的组合物
WO2006071618A1 (en) *	2004-12-23	2006-07-06	Novartis Ag	Compounds for flaviviridae treatment
ATE524183T1 (de) *	2005-06-17	2011-09-15	Novartis Ag	Verwendung von sanglifehrin bei der hcv-therapie
WO2007011777A2 (en) *	2005-07-18	2007-01-25	Novartis Ag	Small animal model for hcv replication
US8329658B2 (en)	2005-09-30	2012-12-11	Scynexis, Inc.	Arylalkyl and heteroarylalkyl derivatives of cyclosporine A for the treatment and prevention of viral infection
EP1933859A2 (en)	2005-09-30	2008-06-25	Scynexis, Inc.	Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
JP2007112775A (ja) *	2005-10-24	2007-05-10	Hamamatsu Univ School Of Medicine	サイトメガロウイルス感染の処置におけるシクロスポリン類の使用
US8188052B2 (en)	2006-05-19	2012-05-29	Scynexis, Inc.	Method for the treatment and prevention of ocular disorders
BRPI0719189A2 (pt) *	2006-10-12	2018-08-14	Univ Kyushu Nat Univ Corp	uso de ciclosporinas modificadas
WO2008069917A2 (en)	2006-11-20	2008-06-12	Scynexis, Inc.	Novel cyclic peptides
CA2724523A1 (en)	2008-06-06	2010-01-07	Scynexis, Inc.	Novel macrocyclic peptides
US8536114B2 (en)	2008-12-31	2013-09-17	Scynexis, Inc.	Macrocycles
US10752611B2 (en)	2009-02-27	2020-08-25	Enanta Pharmaceuticals, Inc.	Benzimidazole derivatives
AU2010313497B2 (en)	2009-10-30	2013-08-01	Boehringer Ingelheim International Gmbh	Dosage regimens for HCV combination therapy comprising BI201335, interferon alpha and ribavirin
JP5536229B2 (ja) *	2009-12-18	2014-07-02	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｈｃｖ併用療法
MX2013003903A (es)	2010-10-05	2013-05-20	Novartis Ag	Nuevos tratamientos de infeccion por el virus de hepatitis c.
RU2013129824A (ru)	2010-11-30	2015-01-10	Новартис Аг	Новое лечение инфекции вируса гепатита с
JO3337B1 (ar)	2010-12-13	2019-03-13	Debiopharm Sa	تركيبات صيدلية تشمل أليسبوريفير
JP2014509628A (ja)	2011-03-31	2014-04-21	ノバルティスアーゲー	Ｃ型肝炎ウイルス感染症を治療するためのアリスポリビル
PL2694087T3 (pl)	2011-04-01	2015-06-30	Novartis Ag	Leczenie zakażenia wirusem zapalenia wątroby typu B samego lub w połączeniu z zakażeniem wirusem zapalenia wątroby typu delta i towarzyszącymi chorobami wątroby
KR20140011379A (ko)	2011-04-13	2014-01-28	노파르티스 아게	알리스포리비르를 사용하는 c형 간염 바이러스 감염의 치료
AU2012314517A1 (en)	2011-09-27	2014-04-17	Novartis Ag	Alisporivr for treatment of Hepatis C virus infection
US20150133369A1 (en)	2012-05-07	2015-05-14	Steven Kovacs	Pharmacokinetic modulation with alisporivir
WO2015008223A1 (en)	2013-07-17	2015-01-22	Novartis Ag	Treatment of hepatitis c virus infection with alisporivir and ribavirin
WO2015017382A1 (en)	2013-07-29	2015-02-05	Enanta Pharmaceuticals, Inc.	Hepatitis c virus inhibitors
WO2015136455A1 (en)	2014-03-13	2015-09-17	Novartis Ag	New treatments of hepatitis c virus infection
CN120887906A (zh)	2016-05-10	2025-11-04	C4医药公司	用于靶蛋白降解的螺环降解决定子体
CN109641874A (zh)	2016-05-10	2019-04-16	C4医药公司	用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
EP3454856B1 (en)	2016-05-10	2024-09-11	C4 Therapeutics, Inc.	Heterocyclic degronimers for target protein degradation
CN109790143A (zh)	2016-05-10	2019-05-21	C4医药公司	用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
WO2018237026A1 (en)	2017-06-20	2018-12-27	C4 Therapeutics, Inc.	N / O-LINKED DEGRONS AND DEGRONIMERS FOR DEGRADATION OF PROTEINS

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5639724A (en) *	1984-07-24	1997-06-17	Sandoz Ltd.	Cyclosporin galenic forms
SK278808B6 (sk) *	1990-11-02	1998-03-04	Novartis Ag	Cyklosporíny, ich použitie pri príprave liečiva na
US5908621A (en) *	1995-11-02	1999-06-01	Schering Corporation	Polyethylene glycol modified interferon therapy
FR2757522B1 (fr) *	1996-12-24	1999-01-29	Rhone Poulenc Rorer Sa	Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757521B1 (fr) *	1996-12-24	1999-01-29	Rhone Poulenc Rorer Sa	Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
JPH1180026A (ja) *	1997-09-02	1999-03-23	Yoshitomi Pharmaceut Ind Ltd	新規免疫抑制剤、その使用方法およびその同定方法
US20030216303A1 (en)	1998-03-06	2003-11-20	Michael Ambuhl	Emulsion preconcentrates containing cyclosporin or a macrolide
GB9811854D0 (en)	1998-06-02	1998-07-29	Ciba Geigy Ag	Organic compounds
EP1372695A2 (en) *	2000-10-19	2004-01-02	Fujisawa Pharmaceutical Co., Ltd.	Cell damage inhibitor
AR036081A1 (es) *	2001-06-07	2004-08-11	Smithkline Beecham Corp	Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
US20030213603A1 (en) *	2002-05-14	2003-11-20	Fisher David B.	Dual use extension apparatus for a tool
AP2005003213A0 (en) *	2002-06-28	2005-03-31	Univ Cagliari	2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections.
KR20050089799A (ko) *	2002-10-29	2005-09-08	콜리 파마슈티칼 그룹, 리미티드	Ｃ형 간염 바이러스 감염의 치료에 있어 ＣｐＧ올리고뉴클레오티드의 용도
CN100335492C (zh) *	2002-12-23	2007-09-05	埃迪尼克斯(开曼)有限公司	生产3’－核苷前体药物的方法
GB0320638D0 (en)	2003-09-03	2003-10-01	Novartis Ag	Organic compounds
KR101191833B1 (ko)	2004-10-01	2012-10-16	데비오팜 에스 에이	씨형 간염 감염의 치료용［디-멜라］3-［에트발］4-시클로스포린의 이용 및 상기［디-멜라］3-［에트발］4-시클로스포린으로 구성되는 약학 조성물
CN101076350A (zh)	2004-12-23	2007-11-21	诺瓦提斯公司	用于hcv治疗的组合物

2005
- 2005-12-20 CN CNA2005800424402A patent/CN101076350A/zh active Pending
- 2005-12-20 RU RU2007128099/15A patent/RU2007128099A/ru not_active Application Discontinuation
- 2005-12-20 KR KR1020077014269A patent/KR20070087624A/ko not_active Withdrawn
- 2005-12-20 MX MX2007007779A patent/MX2007007779A/es not_active Application Discontinuation
- 2005-12-20 JP JP2007548377A patent/JP2008525459A/ja active Pending
- 2005-12-20 BR BRPI0519345-1A patent/BRPI0519345A2/pt not_active IP Right Cessation
- 2005-12-20 US US11/720,105 patent/US7897565B2/en not_active Expired - Fee Related
- 2005-12-20 EP EP05854722A patent/EP1830871A1/en not_active Withdrawn
- 2005-12-20 AU AU2005322242A patent/AU2005322242B2/en not_active Ceased
- 2005-12-20 CA CA002587793A patent/CA2587793A1/en not_active Abandoned
- 2005-12-20 NZ NZ555143A patent/NZ555143A/en not_active IP Right Cessation
- 2005-12-20 WO PCT/US2005/046059 patent/WO2006071619A1/en not_active Ceased
2007
- 2007-05-15 ZA ZA200703908A patent/ZA200703908B/xx unknown
- 2007-06-04 IL IL183659A patent/IL183659A0/en unknown
- 2007-06-18 MA MA30000A patent/MA29098B1/fr unknown
- 2007-07-19 NO NO20073764A patent/NO20073764L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
US20090104149A1 (en)	2009-04-23
KR20070087624A (ko)	2007-08-28
US7897565B2 (en)	2011-03-01
EP1830871A1 (en)	2007-09-12
IL183659A0 (en)	2007-09-20
RU2007128099A (ru)	2009-01-27
MA29098B1 (fr)	2007-12-03
AU2005322242B2 (en)	2010-02-11
NZ555143A (en)	2009-12-24
JP2008525459A (ja)	2008-07-17
CN101076350A (zh)	2007-11-21
AU2005322242A1 (en)	2006-07-06
ZA200703908B (en)	2009-06-24
CA2587793A1 (en)	2006-07-06
WO2006071619A1 (en)	2006-07-06
BRPI0519345A2 (pt)	2009-01-20
MX2007007779A (es)	2007-08-14

Legal Events

Date	Code	Title	Description
2011-07-25	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20073764L (no)	2007-09-18	Sammensetninger for behandling av HCV
NO20092053L (no)	2009-07-24	HCV NS3-proteaseinhibitorer
EA200800371A1 (ru)	2008-06-30	Ингибиторы ns3 протеазы вгс
NO20070224L (no)	2007-04-02	2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20091704L (no)	2009-07-27	Inhibitorer av hepatitt C virus
NO20091707L (no)	2009-05-29	Inhibitorer av hepatitt C virus
EP1802650A4 (en)	2008-08-20	SUBSTITUTED CYCLOSPORINE 3-ETHER AND 3-THIOETHER DERIVATIVES FOR THE TREATMENT AND PREVENTION OF HEPATITIS C INFECTION
NO20073765L (no)	2007-09-19	Forbindelser for behandling av flaviviridae
ATE433447T1 (de)	2009-06-15	Pyrimiidinverbindungen
NO20081086L (no)	2008-04-30	Makrosykliske peptider som HCV NS3-proteaseinhibitorer
NO20061479L (no)	2006-06-02	Anvendelse av modifiserte cyklosporiner for behandling av HCV-forstyrrelser
NO20080150L (no)	2008-03-10	Inhibitorer av AKT-aktivitet
NO20091706L (no)	2009-07-21	Inhibitorer av hepatitt C virus
NO20050525L (no)	2005-05-06	Benzimidazol-1-yl-tiofenforbindelser for behandling av cancer
NO20080338L (no)	2008-02-29	Forbindelser for behandling av multilegemiddelresistente bakterielle infeksjoner
GB0612423D0 (en)	2006-08-02	Therapeutic agents
NO20081844L (no)	2008-05-29	Terapeutiske forbindelser
EA200702493A1 (ru)	2008-04-28	Соединения и способы лечения или предотвращения флавивирусных инфекций
NO20063449L (no)	2006-07-27	Substituerte heterocykler og deres anvendelse
NO20056192L (no)	2005-12-27	Kapaseinhibitorer og anvendelse derav
EA200801997A1 (ru)	2009-04-28	Новые соединения
NO20064078L (no)	2006-09-11	Substituerte azetidinsammensetninger, deres fremstilling og anvendelse som medikamenter
TW200626585A (en)	2006-08-01	18-membered macrocycles and analogs thereof
DK1373220T3 (da)	2007-10-08	Benzimidazoler, som er nyttige ved behandling af seksuel dysfunktion
SE0303480D0 (sv)	2003-12-19	Benzofuranes